Insilico Medicine has signed a major drug discovery agreement with Eli Lilly that could be worth up to $2.75 billion, plus royalties on future sales. The deal grants Lilly an exclusive global license to use Insilico’s Pharma.AI platform across multiple therapeutic areas, covering drug discovery, development, manufacturing, and commercialization. Insilico will receive $115 million upfront, with additional payments tied to development, regulatory, and commercial milestones.
Insilico’s Pharma.AI platform leverages generative AI and large language models to accelerate the entire drug development process—from identifying disease targets and biomarkers to designing small-molecule and biologic therapies. The companies will collaborate on multiple research programs, combining Insilico’s AI capabilities with Lilly’s disease expertise and development infrastructure. Lilly will determine the specific therapeutic focus areas for the partnership.
Company leaders said the collaboration reflects growing confidence in AI-driven drug discovery as a way to tackle complex diseases and reduce development timelines. Insilico CEO Alex Zhavoronkov emphasized the platform’s ability to identify targets across multiple diseases simultaneously, with the goal of delivering transformative therapies for areas of high unmet need.
The deal is part of a broader trend of partnerships between AI biotech firms and large pharmaceutical companies. Insilico has recently signed multiple collaborations across oncology, neurology, autoimmune, and cardiometabolic diseases, including agreements with Servier, China Medical System, Qilu Pharmaceutical, and Tenacia Biotechnology. The company also went public in Hong Kong in late 2025, raising approximately $290 million.
Click here to read the original news story.